Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Pfizer to make Gilead’s remdesivir COVID-19 treatment

By Sean Whooley | August 7, 2020

Pfizer (NYSE:PFE) announced today that it entered into a multi-year agreement with Gilead Sciences (NSDQ:GILD) to manufacture and supply its antiviral remdesivir treatment.

The investigational antiviral remdesivir will be manufactured by Pfizer under the agreement as the company becomes one of the multiple external manufacturing organizations supporting efforts to scale up the supply of the investigational treatment for COVID-19. Pfizer will offer contract manufacturing services at its McPherson, Kan.-based facility to supply remdesivir for Gilead.

Gilead’s remdesivir received FDA emergency use authorization (EUA) to treat severely ill COVID-19 patients in May, and the company has since licensed it out in non-exclusive, voluntary agreements with companies including Mylan (NSDQ:MYL), Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences.

Pfizer, meanwhile, has been developing a COVID-19 vaccine in collaboration with BioNTech (NSDQ:BNTX). Pfizer recently agreed to a $1.95 billion deal with the U.S. Dept. of Health and Human Services and the U.S. Defense Dept. to produce and deliver 100 million doses of a COVID-19 vaccine.

“From the beginning, it was clear that no one company or innovation would be able to bring an end to the COVID-19 crisis,” Pfizer chairman & CEO Albert Bourla said in a news release. “Pfizer’s agreement with Gilead is an excellent example of members of the innovation ecosystem working together to deliver medical solutions. Together, we are more powerful than alone.

“As one of the largest manufacturers of vaccines, biologics and sterile injectables, it is a privilege to offer our expertise and infrastructure to help fight this pandemic. In that spirit, we are pleased that Gilead is using our manufacturing capacity to help facilitate supply of this medicine to patients as quickly as possible.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

Wuxi AppTec
WuXi STA constructing manufacturing facility in Middletown, Delaware
analyzing medical sample
Expert answers to nitrosamine impurity questions
Touchlight
Touchlight inks patent license deal with Pfizer related to the use of dbDNA in mRNA products
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards